Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2014

View Archived Issues

Genzyme establishes collaboration to develop gene therapy for Leber's congenital amaurosis

Baxter and Merrimack sign ex-U.S. license agreement for MM-398

Celldex Therapeutics begins pilot study of CDX-301

Alnylam begins study examining the prevalence of TTR mutations in cardiac amyloidosis

Diaxonhit completes enrollment in validation study of BJI InoPlex

Repros reports data from second pivotal study of Androxal for secondary hypogonadism

Additional approval obtained for pediatric administration of Vfend in Japan

Pfizer completes InnoPharma acquisition

MicroBiome's NM-505 may improve tolerability of metformin in type 2 diabetes

Bayer presents data from 11-year follow-up of the BENEFIT trials

ARN-2508, an orally available therapeutic for the potential treatment of pain and inflammation

Researchers from Visterra present a novel humanized antibody against dengue virus

SostAb shows promise for fracture healing in animal models of type 1 diabetes

Merck & Co. patents novel LRRK2 inhibitors

Roche divulges new agents for HCV infection

Novel anticancer agents disclosed by TD2

EMA committee recommends approval of Rezolsta, announces darunavir label extensions

New NS5B inhibitors presented by Bristol-Myers Squibb

Influenza drug Avigan administered to patient with Ebola

Roche presents new BTK inhibitors

Lymphoseek recommended by CHMP for sentinel lymph node detection

Bristol-Myers Squibb provides milestone update for Opdivo

FDA grants multiple orphan drug designations to aldoxorubicin

NeuroGenetic cleared to begin phase I trials of NGP-555 for Alzheimer's disease

FDA awards orphan drug designation to Insys Therapeutics' cannabidiol for glioma

Daiichi Sankyo and Ambit Biosciences enter merger agreement

Pegylated liposomal mitomycin-C lipid-based prodrug shows promise in phase I trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...